Tisotumab vedotin, also known as HuMax-TF, HuMax®-TF-ADC or TF-011-MMAE, is an antibody-drug conjugate or ADC targeted to Tissue Factor (TF), a protein involved in tumor signaling and angiogenesis.
Based on its high expression on many solid tumors and its rapid internalization, Tissue Factor (TF) is considered a suitable target for antibody-drug conjugates. In pre-clinical trials tisotumab vedotin has shown strong ability to bind to TF and inhibit tumor growth.
Tisotumab vedotin includes a antibody targeting Tissue Factor (TF) conjugated with monomethyl auristatin E (MMAE) via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker.
Genmab and Seattle Genetics are jointly developing tisotumab vedotin, which is currently in Phase I trials to treat multiple solid tumors.
Last Editorial Review: November 10, 2016
Copyright © 2016 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.